Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: Continued evidence of the importance of the dopamine system in the schizophrenia spectrum

Margaret M. McClure, Philip D. Harvey, Marianne Goodman, Joseph Triebwasser, Antonia New, Harold W. Koenigsberg, Larry J. Sprung, Janine D. Flory, Larry J. Siever

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Cognitive deficits observed in schizophrenia are also frequently found in individuals with other schizophrenia spectrum disorders, such as schizotypal personality disorder (SPD). Dopamine appears to be a particularly important modulator of cognitive processes such as those impaired in schizophrenia spectrum disorders. In a double-blind, placebo-controlled clinical trial, we administered pergolide, a dopamine agonist targeting D 1 and D 2 receptors, to 25 participants with SPD and assessed the effect of pergolide treatment, as compared with placebo, on neuropsychological performance. We found that the pergolide group showed improvements in visual-spatial working memory, executive functioning, and verbal learning and memory. These results suggest that dopamine agonists may provide benefit for the cognitive abnormalities of schizophrenia spectrum disorders.

Original languageEnglish (US)
Pages (from-to)1356-1362
Number of pages7
JournalNeuropsychopharmacology
Volume35
Issue number6
DOIs
StatePublished - May 1 2010
Externally publishedYes

Keywords

  • Cognition
  • Dopamine
  • Pergolide
  • Schizophrenia spectrum
  • Schizotypal personality
  • Schizotypy

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: Continued evidence of the importance of the dopamine system in the schizophrenia spectrum'. Together they form a unique fingerprint.

  • Cite this